Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

• Histologically or cytologically proven solid tumor
• Measurable or evaluable disease
• Refractory to standard treatment
• No prior failure of a docetaxel and carboplatin regimen except in the adjuvant setting
• History of brain disease allowed, provided the following criteria are met:
• Brain disease previously treated with radiotherapy or surgery
• Asymptomatic with no active brain disease, as documented by CT scan or MRI, for at least 3 months

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Creatinine ≤ 1.5 mg/dL
• Bilirubin normal
• AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if hepatic metastases are present)
• Alkaline phosphatase ≤ 3 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment
• No serious medical condition, laboratory abnormality, or psychiatric illness that would preclude giving informed consent, expose the patient to unacceptable risk, or affect the interpretation of study data
• No known hypersensitivity to thalidomide
• No history of erythema nodosum, characterized by a desquamating rash, while taking thalidomide or similar drugs
• No pre-existing peripheral neuropathy ≥ grade 2
• No known hypersensitivity or intolerance to taxanes
• No known HIV positivity
• No known infectious hepatitis, types A, B, or C

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No more than 2 prior chemotherapy regimens
• At least 28 days since prior cancer therapy, including radiotherapy, biologic therapy, hormonal therapy, chemotherapy, or surgery
• At least 28 days since any other prior investigational drug or therapy
• No prior lenalidomide
• No other concurrent chemotherapy or biologic therapy
• No concurrent radiotherapy
• No concurrent use of any other anticancer agents or treatments
• No prophylactic granulocyte colony-stimulating factors (G-CSF) during the first course of study treatment
• No concurrent prophylactic antibiotics
• No concurrent treatment with the following medications:
• Systemic corticosteroids (except as prophylaxis for docetaxel administration)
• Estrogens
• Azoles
• Macrolides
• Cyclosporine
• Rifampin
• Phenytoin